Trial Profile
A 12 Month, Phase III, Randomized, Double-masked, Multicenter, Active-controlled Study to Evaluate the Efficacy and Safety of Two Different Dosing Regimens of 0.5 mg Ranibizumab vs. Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularisation Secondary to Pathologic Myopia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary) ; Verteporfin
- Indications Choroidal neovascularisation; Degenerative myopia
- Focus Registrational; Therapeutic Use
- Acronyms RADIANCE
- Sponsors Novartis
- 05 Jan 2017 According to a Genentech media release, the US FDA has approved ranibizumab (Lucentis) for the treatment of patients with myopic choroidal neavascularization based on results from this trial.
- 11 Oct 2016 According to a Roche media release, the US FDA has accepted a supplemental Biologics License Application (sBLA) for ranibizumab (Lucentis) for review for the treatment of myopic choroidal neovascularization based on results from this trial.
- 15 Aug 2014 New trial record